Ending the Prohibition: Modern Hormone Therapy for Breast Cancer Survivors

Systemic hormone therapy has long been contraindicated in women with a history of breast cancer, particularly those with hormone receptor positive (HR+) disease. This clinical orientation has largely been shaped by the early termination of the HABITS trial (2004), which suggested increased recurrence risk with oral hormone therapy (estradiol hemihydrate ± norethisterone acetate). This article revisits the evidence that informs current guidelines, critically reviews the limitations of the HABITS and Stockholm trials, and presents emerging real-world data on the safety of modern hormone regimens. No randomized trial has ever directly tested modern, physiologicdose transdermal estradiol (E2) + oral micronized progesterone (P4) in HR+ breast-cancer survivors, yet guidelines uniformly contraindicate all hormone therapy on theoretical grounds. Contemporary evidence demonstrates a distinctly different risk assessment. Modern bioidentical regimens do not demonstrate increased breast cancer recurrence or mortality in observational data, and the absence of evidence of harm across all tumor subtypes does not justify absolute contraindication. These findings demonstrate that blanket prohibitions against hormone therapy are unsupported by modern data and mechanistic understanding. This article delineates why older evidence is non-analogous to current regimens, integrates recent real-world outcomes, and proposes a framework that restores ethical equilibrium between evidence, risk minimization, and patient autonomy. This Version 2.0 supersedes the August 2025 publication to correct a citation error and integrate updated evidence. The previous version mis-cited Xu et al., 2022 (SEER-Medicare); the verified and correct citation is Batur P, Blixen CE, Moore HC, Thacker HL, Xu M (2006). Maturitas 53(2): 123–132. doi: 10.1016/j.maturitas.2005.03.004. The revision also incorporates McVicker 2024 and Beste 2025, and adds a sidebar “Evidentiary Asymmetry: HABITS vs Batur.” Substantive conclusions remain unchanged and are further supported by corrected evidence. Readers should treat Version 2.0 as the definitive citable edition; the original DOI remains valid for archival reference.